Biologically Active Substance – Page 26

Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda

11 months ago talkbio0Tagged ASCO, Beginning, Cancer Vaccines, Keytruda, melanoma, Merck, Moderna, pilot program, RNA, Messenger, United States Food and Drug Administration

Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program

FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product

11 months ago talkbio0Tagged Approved, COVID19 (disease), Moderna, mRESVIA, Respiratory syncytial virus, RNA, Messenger, Spikevax, United States Food and Drug Administration, Vaccines

Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA

Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers

11 months ago talkbio0Tagged Asahi Kasei, Biological Factors, Bionova, CDMO, Cells, DNA, Facility (object), gene therapy, Plasmids, Science, Texas

Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility

Miniature Swine: Revolutionizing Nonclinical Studies for Small Molecules and Biologics

11 months ago talkbio0Tagged Biological Factors, dermal testing, Evaluation procedure, nonclinical studies, Safety, Scientific model, Small Molecule, Swine, Miniature

Miniature swine, Nonclinical studies, Small molecules, Biologics, Dermal testing, Safety assessments, Research models

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

11 months ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results

11 months ago talkbio0Tagged Agonist, Narcolepsy, Narcolepsy type 1, Phase 3 Clinical Trials, TAK-861, Takeda

Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

11 months ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

11 months ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

11 months ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals